+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A phase I/II study of cisplatin and cyclophosphamide with granulocyte-macrophage colony stimulating factor in advanced or relapsed epithelial ovarian cancer



A phase I/II study of cisplatin and cyclophosphamide with granulocyte-macrophage colony stimulating factor in advanced or relapsed epithelial ovarian cancer



British Journal of Cancer 80(Suppl. 2): 107




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034313964

Download citation: RISBibTeXText


Related references

A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer. British Journal of Cancer 69(3): 537-540, 1994

Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. Gynecologic Oncology 77(2): 271-277, 2000

Granulocyte-macrophage colony stimulating factor prior to chemotherapy for advanced epithelial ovarian cancer. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 83(3): 317-318, 2003

A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. Clinical Cancer Research 5(6): 1299-1305, 1999

Chemotherapy with granulocyte colony stimulating factor (G-CSF) alone versus granulocyte colony stimulating factor (G-CSF) plus granulocyte-macrophage stimulating factor (GM-CSF) for hematopoietic progenitor cell mobilization in patients with relapsed non-hodgkin's lymphomas (NHLs).. 2007

A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer 86(11): 2291-2300, 1999

Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. Journal of Clinical Oncology 14(2): 628-635, 1996

Thrombin stimulates synthesis of macrophage colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor by human proximal tubular epithelial cells in culture. Nephron Extra 2(1): 1-8, 2012

A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. Blood 86(8): 2913-2921, 1995

5-Fluorouracil dose intersification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: A phase II study. American Journal of Clinical Oncology 21(3): 313-316, 1998

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. British Journal of Cancer 75(5): 703-709, 1997

Fec (Fluorouracil, epirubicin, cyclophosphamide) plus granulocyte macrophage-colony-stimulating factor (gm-csf) in advanced or inflammatory breast-cancer - a dose-finding study. International Journal of Oncology 3(2): 223-228, 1993

Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results. Japanese Journal of Clinical Oncology 25(5): 208-212, 1995

The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project. American Journal of Clinical Oncology 17(5): 374-81; Discussion 382, 1994

Comparison of neutrophil and monocyte function by microbicidal cell-kill assay in patients with cancer receiving granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, or no cytokine after cytotoxic chemotherapy: a phase II trial. American Journal of Clinical Oncology 21(3): 308-312, 1998